Index

Note: Page numbers of article titles are in **boldface** type.

**A**

Acute otitis media  
in children  
pneumococcus and, 633–634

Airway hyperreactivity  
genetics of, 673–674

Amphotericin B  
lipid preparations of  
for neonatal candidiasis, 607–608

Amphotericin B deoxycholate  
for neonatal candidiasis, 606–607

Anidulafungin  
for neonatal candidiasis, 610–611

Anthrax  
children exposed to  
treatment of, 733–736

Antiretroviral therapy  
in HIV-infected children, 713–729. See also **Human immunodeficiency virus (HIV) infection, children with, antiretroviral therapy in**.

Arthropathy(ies)  
quinolone, 618–621

Asthma  
atopic  
immunopathogenesis of  
environmental influences on, 674–675  
bronchiolitis and  
link between, **667–689**  
described, 667  
recurrent  
after bronchiolitis, 676–683  
viral causes of, 668–670

Astrovirus infections  
diarrhea in children due to, 588–589

Atopy  
bronchiolitis and  
link between, 667–668

Avian influenza virus  
in children, 577–579

**B**

Bacterial agents  
children exposed to  
treatment of, 733–738

*Bartonella* sp.  
in children  
clinical manifestations of, 693–702. See also specific infections.

*Bartonellosis*  
in children, **691–711**  
blood effects, 700  
bone effects, 698–699  
cardiac effects, 699  
clinical manifestations of, 693–702  
diagnosis of, 702–704  
epidemiology of, 692–693  
gastrointestinal system effects, 698  
hepatic effects, 698  
nervous system effects, 695  
ocular effects, 694–695  
organ-specific involvement in, 694–700  
pseudoinfectious mononucleosis due to, 701  
pseudomalignancy due to, 700  
pulmonary effects, 699  
skin effects, 699–700  
 systemic manifestations of, 701–702  
tissue-specific involvement in, 694–700  
treatment of, 704–706

Bioterrorism  
pathogens linked to  
children exposed to  
surveillance of, 741–745  
treatment of, **731–745**  
anthrax, 733–736  
bacterial agents, 733–738  
botulinum toxin, 740  
plague, 737

0891-5520/05/$ - see front matter © 2005 Elsevier Inc. All rights reserved.  
doi:10.1016/S0891-5520(05)00086-3  
id.theclinics.com
Bioterrorism (continued)
ricin, 740–741
smallpox, 738–739
Staphylococcal aureus enterotoxin, 740
Toxins, 739–741
tularemia, 737–738
viral agents, 738–739
viral hemorrhagic fevers, 739

Blood
Bartonella sp. effects on, 700

Bone(s)
Bartonella sp. effects on, 698–699

Bone disease
in HIV-infected children, 720–721

Botulinum toxin
children exposed to treatment of, 740

Bronchiolitis
asthma and link between, 667–689
atopy and link between, 667–668
clinical features of, 667
described, 667
hospitalization due to, 667
pathogenesis of, 670–673
prevalence of, 667
recurrent wheezing and asthma after development of, 676–683
viral causes of, 668–670

C
Calicivirus infection
diarrhea in children due to, 587–588

Campylobacter infections
diarrhea in children due to, 590

Candidiasis
neonatal, 603–615. See also Neonatal candidiasis.

Cardiovascular disease
lipodystrophy and, 714–716

Caspofungin
for neonatal candidiasis, 610–611

Cat-scratch disease
Bartonella sp. and, 694

Children
acute otitis media in pneumococcus and, 633–634
bartonellosis in, 691–711. See also Bartonellosis, in children.
diarrhea in, 585–602. See also Diarrhea, in children.

exposure to pathogens linked to bioterrorism treatment of, 731–745. See also Bioterrorism, pathogens linked to, children exposed to, treatment of.

fluoroquinolones in, 617–628. See also Fluoroquinolone(s), in infants and children.

HIV infection in antiretroviral therapy in, 713–729. See also Human immunodeficiency virus (HIV) infection, children with, antiretroviral therapy in.

hospitalized health care–acquired infections as threat to, 647

LRIs in, 569–584. See also specific infection.
methicillin-resistant Staphylococcus aureus as community-acquired pathogen in implications of, 747–757. See also Methicillin-resistant Staphylococcus aureus, as community-acquired pathogen in pediatric patients.

nalidixic acid in, 618–619

newly identified respiratory tract viruses in. See specific virus and Respiratory tract viruses, newly identified, in children.
clinical presentation and outcomes of, 569–584. See also Respiratory tract viruses, newly identified, in children.

pneumococcal disease in in U.S. epidemiology of, 629–645. See also Pneumococcal disease, in children, in U.S.
pneumonia in, 632

Clostridium difficile
diarrhea in children due to, 594–596

Community-acquired pathogens in pediatric patients methicillin-resistant Staphylococcus aureus as implications of, 747–757. See also Methicillin-resistant...
Staphylococcus aureus, as community-acquired pathogen in pediatric patients.

Coronavirus(es)
in children, 574–577
in Netherlands, 576–577
SARS-CoV, 574–576

Cryptosporidiosis
diarrhea in children due to, 597

Diarrhea
in children, 585–602
causes of, 585–586
astrovirus infections, 588–589
bacterial, 589–596
calicivirus infection, 587–588
Campylobacter infections, 590
Clostridium difficile, 594–596
cryptosporidiosis, 597
enteric adenovirus infections, 589
Escherichia coli, 593–594
Giardia intestinalis infections, 596–597
parasitic, 596–597
rotavirus infections, 586–587
Salmonella infections, 590–591
Shigella infections, 592–593
viral, 586–588
management of, 598–599
morbidity and mortality due to, 585
prevention of, 598

Dyslipidemia
in HIV-infected children, 716–718

Echinocandin(s)
for neonatal candidiasis, 610–611
neonatal meningocencephalitis due to, 611–612

Enteric adenovirus infections
diarrhea in children due to, 589

Enterotoxin(s)
Staphylococcal aureus
children exposed to
treatment of, 740

Environment
as factor in immunopathogenesis of atopic asthma, 674–675

Escherichia coli
diarrhea-associated
in children, 593–594

Eye(s)
Bartonella sp. effects on, 694–695

Fluconazole
for neonatal candidiasis, 608–610

Flucytosine
for neonatal candidiasis, 608

Fluoroquinolone(s)
in infants and children, 617–628
bacterial resistance due to, 621–622
described, 617–618
indications for, 623–624
pharmacology of, 622–623

Gastrointestinal system
Bartonella sp. effects on, 698

Giardia intestinalis infections
diarrhea in children due to, 596–597

Health care–acquired infections
as threat to safety of hospitalized children, 647
multiple drug–resistant organisms and, 660–661
reference data in, 648–649
classic epidemiology and new quality improvement techniques similarities between, 648
prevention of, 651–653
public reporting of, 649–650
within pediatric health care setting epidemiology of, 653–660
infections related to medical devices, 654–658
central venous catheter–related, 655–656
ventilator–associated pneumonia, 656–658
mycobacterium tuberculosis, 659
Health care–acquired (continued)
surgical site infections, 658–659
urinary tract infections, 658
viral pathogens, 659–660
transmission of, 650–651
Heart
Bartonella sp. effects on, 699
Hemorrhagic fever
viral
children exposed to treatment of, 739
Hendra virus
in children, 579–580
HIV infection. See Human immunodeficiency virus (HIV) infection.
hMPV. See Human metapneumovirus (hMPV).
Human immunodeficiency virus (HIV) infection
children with antiretroviral therapy in,
713–729
bone disease due to, 720–721
cardiovascular disease due to, 714–716
dyslipidemia due to, 716–718
insulin resistance due to, 718–720
lipodystrophy due to, 714–716
mitochondrial toxicity due to, 721
tolerability of, 713–714
Human metapneumovirus (hMPV)
in children, 570–574
clinical presentation of, 572–573
coinfections with other viruses, 573–574
discovery of, 570
diversity of, 570–571
epidemiology of, 571–572
high-risk populations, 573
Infant(s)
fluoroquinolones in, 617–628. See also Fluoroquinolone(s), in infants and children.
immunologic immaturity of, 675–676
Insulin resistance
in HIV-infected children, 718–720
L
Lipodystrophy
cardiovascular disease and, 714–716
management of, 716
Liver
Bartonella sp. effects on, 698
Lower respiratory infections (LRIs)
in children, 569–584
LRIs. See Lower respiratory infections (LRIs).
Lung(s)
Bartonella sp. effects on, 699
M
Meningoencephalitis
neonatal echinocandins and, 611–612
Methicillin-resistant Staphylococcus aureus as community-acquired pathogen in pediatric patients
clinical manifestations of, 748–751
epidemiology of, 747–748
implications of, 747–757
laboratory studies of, 751–752
prevention of, 753–754
treatment of, 752–753
Micafungin
for neonatal candidiasis, 610–611
Mitochondrial toxicity
in HIV-infected children, 721
Mononucleosis
pseudoinfectious
Bartonella sp. and, 701
N
Nalidixic acid, 618–621
animal experiments with, 619
history of, 618
in children, 618–619
published data related to, 620
tendinopathy due to, 620–621
National Nosocomial Infections Surveillance (NNIS) system, 648
Neonatal candidiasis, 603–615
epidemiology of, 603–604
prevention of, 604–606
treatment of, 606–612
amphotericin B deoxycholate in, 606–607
anidulafungin in, 610–611
caspofungin in, 610–611
echinocandins in, 610–611
fluconazole in, 608–610
flucytosine in, 608
lipid preparations of
amphotericin B in,
607–608
micafungin in, 610–611
voriconazole in, 608–610

Neonatal meningoencephalitis
echinocandins and, 611–612

Nervous system
Bartonella sp. effects on, 695

Nipah virus
in children, 579–580

O
Otitis media
acute
in children
pneumococcus and,
633–634

P
Plague
children exposed to
pathogens linked to, 737

Pneumococcal conjugate vaccine (PCV7)
in pneumococcal disease prevention in
children, 629–645. See also
Pneumococcal disease, in children,
in U.S.
characteristics favoring improved
efficacy over time, 636–637
characteristics reducing efficacy
over time, 637–639
cost-effectiveness of, 634–635
described, 629–631
effects on antibiotic use, 636–637
effects on pneumococcal
epidemiology, 635–639
efficacy of, 631–634
failure of, 637–638
in serotype replacement, 638
in serotype switching, 638–639
influence on proportion of
antibiotic-nonsusceptible
pneumococcus, 635
success of, 639–640
in young febrile child, 639–640

Pneumococcal disease
in children
acute otitis media due to,
633–634

Q
Quinolone arthropathy, 618–621
Quinolone-induced cartilage toxicity
monitoring for, 619–620

R
Respiratory tract viruses
newly identified
in children
avian influenza virus,
577–579
clinical presentation and
outcomes of, 569–584
coronaviruses, 574–577
Hendra virus, 579–580
human metapneumovirus,
570–574
Nipah virus, 579–580

Ricin
children exposed to
treatment of, 740–741

Rotavirus infections
diarrhea in children due to, 586–587

S
Salmonella infections
diarrhea in children due to, 590–591
SARS-CoV. See *Severe acute respiratory syndrome–coronavirus (SARS-CoV).*

Severe acute respiratory syndrome–coronavirus (SARS-CoV) in children, 574–576

*Shigella* infections
diarrhea in children due to, 592–593

Skin
*Bartonella* sp. effects on, 699–700

Smallpox
children exposed to
treatment of, 738–739

*Staphylococcal aureus* enterotoxin
children exposed to
treatment of, 740

*Staphylococcus aureus*
methicillin-resistant
as community-acquired pathogen in pediatric patients

See also
*Methicillin-resistant Staphylococcus aureus,*
as *community-acquired pathogen in pediatric patients.*

---

**T**

Toxin(s)
children exposed to
treatment of, 739–741

*Tularemia*
children exposed to
treatment of, 737–738

---

**V**

Ventilator-associated pneumonia
in pediatric health care setting,
656–658

Viral agents
children exposed to
treatment of, 738–739

Viral hemorrhagic fevers
children exposed to
treatment of, 739

Voriconazole
for neonatal candidiasis, 608–610

---

**W**

Wheezing
recurrent
after bronchiolitis, 676–683